NYMOX PHARMACEUTICAL CORP Quarterly Research And Development Expense in USD from Q1 2017 to Q3 2023

Taxonomy & unit
ifrs-full: USD
Summary
Nymox Pharmaceutical Corp quarterly/annual Research And Development Expense history and growth rate from Q1 2017 to Q3 2023.
  • Nymox Pharmaceutical Corp Research And Development Expense for the quarter ending September 30, 2023 was $661K, a 25.9% decline year-over-year.
  • Nymox Pharmaceutical Corp Research And Development Expense for the twelve months ending September 30, 2023 was -$288K, a 104% decline year-over-year.
  • Nymox Pharmaceutical Corp annual Research And Development Expense for 2022 was $3.77M, a 43.3% decline from 2021.
  • Nymox Pharmaceutical Corp annual Research And Development Expense for 2021 was $6.66M, a 18% decline from 2020.
  • Nymox Pharmaceutical Corp annual Research And Development Expense for 2020 was $8.12M, a 10.1% increase from 2019.
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$288K $661K -$231K -25.9% Jul 1, 2023 Sep 30, 2023 6-K 2023-11-15
Q2 2023 -$57K $594K -$216K -26.7% Apr 1, 2023 Jun 30, 2023 6-K 2023-08-14
Q1 2023 $159K $720K -$3.61M -83.4% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-12
Q4 2022 $3.77M -$2.26M -$3.59M -271% Oct 1, 2022 Dec 31, 2022 20-F 2023-05-02
Q3 2022 $7.36M $892K -$947K -51.5% Jul 1, 2022 Sep 30, 2022 6-K 2023-11-15
Q2 2022 $8.31M $810K -$1.26M -60.8% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-14
Q1 2022 $9.57M $4.33M +$2.91M +204% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-12
Q4 2021 $6.66M $1.33M +$152K +12.9% Oct 1, 2021 Dec 31, 2021 20-F 2023-05-02
Q3 2021 $6.51M $1.84M -$1.4M -43.2% Jul 1, 2021 Sep 30, 2021 6-K/A 2022-11-16
Q2 2021 $7.9M $2.07M -$88K -4.08% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-15
Q1 2021 $7.99M $1.43M -$130K -8.36% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-13
Q4 2020 $8.12M $1.17M -$630K -34.9% Oct 1, 2020 Dec 31, 2020 20-F 2023-05-02
Q3 2020 $8.75M $3.24M +$1.73M +115% Jul 1, 2020 Sep 30, 2020 6-K 2021-11-12
Q2 2020 $7.02M $2.16M -$180K -7.71% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-13
Q1 2020 $7.2M $1.56M -$174K -10.1% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-14
Q4 2019 $7.38M $1.8M +$287K +18.9% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-30
Q3 2019 $7.09M $1.51M -$146K -8.83% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-13
Q2 2019 $7.24M $2.34M +$787K +50.8% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-14
Q1 2019 $6.45M $1.73M -$228K -11.7% Jan 1, 2019 Mar 31, 2019 6-K 2020-05-14
Q4 2018 $6.68M $1.52M -$943K -38.3% Oct 1, 2018 Dec 31, 2018 20-F 2021-03-29
Q3 2018 $7.62M $1.65M -$499K -23.2% Jul 1, 2018 Sep 30, 2018 6-K 2019-11-13
Q2 2018 $8.12M $1.55M -$36K -2.27% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-14
Q1 2018 $8.16M $1.96M +$281K +16.8% Jan 1, 2018 Mar 31, 2018 6-K 2019-05-15
Q4 2017 $7.87M $2.46M Oct 1, 2017 Dec 31, 2017 20-F 2020-03-30
Q3 2017 $2.15M Jul 1, 2017 Sep 30, 2017 6-K 2018-11-13
Q2 2017 $1.59M Apr 1, 2017 Jun 30, 2017 6-K 2018-08-13
Q1 2017 $1.68M Jan 1, 2017 Mar 31, 2017 6-K 2018-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.